J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

The approved ANDA is therapeutically equivalent to GlaxoSmithKline LLC's Lamictal XR extended-release tablets in strength of ...

Lamotrigine extended-release tablets have an estimated market size of $163 million, as per data for twelve months ending June ...

The "UK Hazardous Goods Logistics Market, By Service Type, By Goods Type, By Location, By Industry: By Region - Market Size, ...

Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing ...

The stock hits an intraday high on Thursday, October 3, 2024, after getting approval from USFDA for general medication drug.

The estimated market value for Lamotrigine Extended-Release Tablets is approximately $163 million for the year ending June ...

Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is a long-term liver condition ...

Alembic has a cumulative total of 216 ANDA approvals (188 final approvals and 28 tentative approvals) from USFDA.

Vadodara: Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug ...

This approval adds to Alembic Pharma's growing portfolio, which now includes 216 ANDA approvals from the USFDA, comprising ...